Hi, all. Here is an interesting article posted about 3 weeks ago on the shifts in funding structure of CME http://www.ama-assn.org/amednews/2011/09/12/prl20912.htm . Even though commercial support from pharma is declining, other sources (academic institutions, non-profits, and docs themselves) are making up the shortfall, and total CME revenue in fact rose 3% in 2010.
This shift in structure may affect some medical education companies that rely on commercial support, but not freelance medical writers who will be needed to write CME no matter how it’s funded. Plus, my company is receiving more requests than ever to write needs assessments to get those limited pharma dollars.
Also, pharma, if spending less money on CME, will likely spend more money on non-CME activities, such as sales training and marketing to spread the word about their drugs.
More reason for optimism… the US FDA has approved 26 new drugs by the end of August this year compared to only 21 NME approved in all of 2010. http://knol.google.com/k/krishan-maggon/new-drug-approvals-fda-2011/3fy5eowy8suq3/148 . New drug approvals are what drives the need for much medical writing work, so that’s good news also.